cardiac diagnostic News
-
Dr. Dwyer joins Coala Life Inc. as new Chief Medical Officer
Coala Life today is pleased to announce the appointment of Jerome V. Dwyer, MD, MBA as Chief Medical Officer – Coala Life, Inc. Dr. Dwyer will oversee the continued development of Coala’s patient-centric solutions that use smart algorithms to digitally transform the field of cardiac diagnostics and help win the battle against the world’s leading cause of death—heart ...
-
Cardiac Biomarker Company Critical Diagnostics Completes $8.5 Million Financing and Announces Two Promotions
Critical Diagnostics, makers of the Presage ST2 Assay and ASPECT-PLUS ST2 Test, both used to help physicians in the management of heart failure patients, today announced it completed an $8.5 million equity financing from a consortium of industry-related investors. Proceeds will be used to continue global commercialization efforts. “We are pleased that such a sophisticated group of ...
-
The long-term solution for stressed New York hearts
Avicenna Cardiology is located on Park Avenue in Manhattan, New York. The clinic is led by Dr. Azadeh Beheshtian, board certified in cardiovascular disease and internal medicine by the American Board of Internal Medicine. Dr. Beheshtian specializes in interventional cardiology and peripheral artery disease, providing top-quality heart care and promoting self-preventive cardiology. Avicenna has ...
-
Positron Enters Long Term Cooperation Agreement with Neusoft Medical Systems
Positron Enters Long Term Cooperation Agreement with Neusoft Medical Systems for the Development and Distribution of Positron’s State of the Art PET/CT System in North America Niagara Falls, NY – January 18, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging company specializing in the field ...
-
CardioWise Receives Supplemental Grant from the National Science Foundation
CardioWise, Inc. has received a National Science Foundation (NSF) Phase IB Small Business Innovation Research grant of $30,000 to continue the development and commercialization of a non-invasive analysis method for detection of heart disease. This award follows and builds on the successful achievement of milestones in a Phase I grant of $150,000 received by the company in January. The Phase IB ...
-
Critical Diagnostics Inks Exclusive Worldwide License Agreement for New Heart Failure Biomarker sNEP
Critical Diagnostics announced today that it entered into a license agreement for the exclusive worldwide rights to the use of the biomarker soluble neprilysin (sNEP) in the diagnosis and monitoring of heart failure patients. Health Sciences Research Institute Germans Trias i Pujol Foundation (IGTP) of Barcelona Spain is the licensor. The neprilysin inhibitor Sacubitril is a key ingredient in a ...
-
CardioWise, Inc. Named a Top-Ten Finalist in Best Cardiovascular Digital Diagnostic Category by UCSF Health Hub
The University of California San Francisco (UCSF) Health Hub has selected CardioWise, Inc. a Digital Health Awards 1st Round (Top Ten) Finalist in its Best Cardiovascular Digital Diagnostic category. The goal of UCSF Digital Health Awards was to select companies that promote faster, better, more cost-effective healthcare by improving outcomes such as shorter hospital stays, reduced patient and ...
-
CardioWise™ Acquires Worldwide Rights to Patent, and Software to Guide Cardiac Resynchronization Therapy Through License Agreement with Johns Hopkins Technology Ventures
CardioWise, Inc., is pleased to announce that the company has acquired the worldwide rights to Image Toolbox heart functional analysis software, and pending patent from Johns Hopkins Technology Ventures through a license agreement. The US Patent application was filed November 11, 2016. The software uses cardiac CT patient data sets to determine which heart failure patients may benefit from ...
-
CardioWise Completes Small Business Innovation and Research Grant from the National Science Foundation
CardioWise, Inc. has completed National Science Foundation (NSF) Phase I and IB Small Business Innovation and Research (SBIR) grants that continued the development and commercialization of a non-invasive analysis method for detection of heart disease. The final report submitted to the NSF in December detailed the research and development milestones that were achieved during the 2013 award period ...
-
William A. (Bill) Breukelman Named to CardioWise, Inc. Board of Directors
An internationally recognized entrepreneur, Mr. Breukelman is a pioneer in imaging technology, initially as principal and chairman of IMAX Corporation, followed by significant transformative contributions to medical and scientific research companies in information technology and strategic development. Jack Coats, Chief Executive Officer of CardioWise, Inc., announced that Mr. William A. ...
-
Coremap Completes $10.5 Million Series A Financing
CoreMap announced today it has completed a $10.5 million Series A financing led by Qure Ventures. The round included both existing investors such as Ronny Ginor, MD of Fifth Focus/HRMG Investments and Orbimed Venture Partners, and a diverse group of new strategic, corporate and financial partners. CoreMap was founded in 2016 by Dr. Peter Spector and based on his groundbreaking work concerning the ...
By CoreMap Inc.
-
CardioWise Joins the Lucem Health Innovation Collaborative as a Founding Member
CardioWise® and Lucem Health™ announced that CardioWise has become a founding member of the Lucem Health Innovation Collaborative, a partner program designed to help AI/ML innovation move to the forefront of healthcare. The collaborative launched by Mayo Clinic along with other investing partners will help digital health innovators create, deploy, and commercialize transformational ...
-
Bardy Diagnostics Announces Use of The Carnation Ambulatory Monitor Patch to Measure QT Segments in COVID-19 Patients Using Hydroxychloroquine
Seattle, WA — March 25, 2020 — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today that its Carnation Ambulatory Monitor (“CAM™”) Patch has been chosen for use in protocols to measure QT Segments in COVID-19 patients who have been prescribed Hydroxychloroquine ...
-
Beacon Biosignals announces partnership with Stratus to advance at-home brain monitoring and machine learning-enabled neurodiagnostics
Beacon Biosignals, which applies AI to EEG to unlock precision medicine for brain conditions, today announced a partnership with Stratus, the nation's leading provider of EEG services, to enable expanded clinical trial service capabilities by leveraging Beacon's machine learning neuroanalytics platform. EEG is standard of care in the clinical diagnosis and management of many neurologic diseases ...
-
Bardy Diagnostics Announces CE Mark Certification for 14-Day Carnation Ambulatory Monitor (CAM™) Patch in Europe and Expansion of Home Enrollment Program Amidst COVID-19 Crisis
SEATTLE, May 26, 2020 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it received CE mark certification for the 14-Day version of the Carnation Ambulatory Monitor (“CAM”) patch, the industry’s only P-wave centric ambulatory cardiac patch monitor and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you